Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon and OPDC Sign Collaboration Agreement

Published: Friday, July 25, 2014
Last Updated: Friday, July 25, 2014
Bookmark and Share
Horizon CombinatoRx to perform in-vitro cell line screening of OPDC clinical stage development candidates.

Horizon Discovery Group plc has announced that its Horizon CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) to perform in vitro cell line screening of certain OPDC development candidate(s).

Pursuant to the terms of the contract, Horizon CombinatoRx will be paid $835,000 for work to be substantially completed during 2014.

Horizon Discovery completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc. in June 2014. Horizon CombinatoRx provides its partners access to the unique cHTS platform and Chalice™ analytics software, which enable the screening and analysis of thousands of complementary drug combinations.

Combined with Horizon’s GENESIS™ (rAAV, CRISPR and ZFN) gene editing platform and X-MAN™ isogenic cell line technology, the company offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.

Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “The contract with OPDC represents the continued commercial traction of the CombinatoRx business following the acquisition which was in line with the strategy outlined at the time of Horizon’s IPO. We are delighted that OPDC has chosen to work with us on these screening projects.”

Edwin Rock, M.D., Ph.D., Senior Director, Global Clinical Development, OPDC, said: “As combination therapies emerge as the standard of care in a range of indications, it is important that we identify effective multi-target mechanisms. Using the Horizon CombinatoRx platform to explore our clinical stage programs in the context of combinations may provide us with information to guide development.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon, Abcam Sign License and Supply Agreement
Horizon Discovery Group plc and Abcam plc have announced the formation of a license and supply agreement between the two companies.
Wednesday, September 09, 2015
Horizon Discovery & Thermo Agreement
Horizon Discovery Group plc and Thermo Fisher Scientific sign supply and commercialization agreement, which will see Thermo market and distribute Horizon’s X-MAN cell line collection.
Monday, April 20, 2015
Horizon, Centre for Process Innovation, & University of Manchester Awarded £1.67M Innovate UK Funding
Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform.
Wednesday, February 18, 2015
Scientific News
Novel Tumor Treatment
In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos has been published.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
The Life Story of Stem Cells
A model analyses the development of stem cell numbers in the human body.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Tissue Engineers Recruit Cells to Make Their Own Strong Matrix
Extracellular matrix is the material that gives tissues their strength and stretch. It’s been hard to make well in the lab, but a Brown University team reports new success. The key was creating a culture environment that guided cells to make ECM themselves.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Artificial Kidney Research Gets A Boost
Development of a surgically implantable, artificial kidney — a promising alternative to kidney transplantation or dialysis for people with end-stage kidney disease — has received a $6 million boost.
Improving the Efficiency of Red Blood Cell Production
Study points to way of significantly reducing cost of laboratory-produced cells.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos